EntreMed (ENMD) Initiates ENMD-2076 Phase 2
- Gilead (GILD) Tanks; Analyst Comments on Express Scripts (ESRX) Viekira Pak Announcement (ABBV)
- Achillion Pharma (ACHN) Reports 4.8 Log10 Reduction With ACH-3422
- Pre-Open Stock Movers 12/22: (CZR) (CACQ) (ACHN) Higher; (GILD) (OCN) (NQ) Lower (more...)
- Caesars Entertainment (CZR), Caesars Acquisition (CACQ) Enter Merger Agreement
- The Carlyle Group (CG), Warburg Pincus to Acquire DBRS
EntreMed, Inc. (Nasdaq: ENMD) announced the initiation of a single-center Phase 2 study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Advanced/Metastatic Soft Tissue Sarcoma" at Princess Margaret Hospital where the study is led by Malcolm Moore, MD and Albiruni R.A. Razak, MD.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Enanta Pharma (ENTA) Gains on FDA Approval for AbbVie's (ABBV) VIEKIRA PAK
- Synthetic Biologics (SYN) Reports Positive Topline Results from Phase 1a Trial of SYN-004
- Tekmira Pharma (TKMR) Enters Agreement with Univ. of Oxford for TKM-Ebola-Guinea Studies in W. Africa
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!